News

Harvard Out of Occupied Palestine Boycotts The Crimson Over Allegations of Anti-Palestinian Bias

News

Harvard Employee Fired Following Online Heated Exchange With Jewish Student

News

Encampment Protesters Set Monday Deadline for Harvard to Begin Negotiations

News

73 Harvard Undergrads Win 2024 Hoopes Prize for Senior Theses

News

Faculty of Arts and Sciences to Consider Starting Faculty Senate Planning Process

Science Retracts Paper by Dana-Farber President Over Discrepancies in Multiple Figures

Science retracted a 2006 paper by Dana-Farber Cancer Institute President and CEO Laurie H. Glimcher '72 due to discrepancies in multiple figures.
Science retracted a 2006 paper by Dana-Farber Cancer Institute President and CEO Laurie H. Glimcher '72 due to discrepancies in multiple figures. By Jina H. Choe
By Veronica H. Paulus and Akshaya Ravi, Crimson Staff Writers

The journal Science retracted a 2006 paper by Dana-Farber Cancer Institute President and CEO Laurie H. Glimcher ’72 on Thursday due to discrepancies in several figures, following data manipulation allegations against her and three other DFCI executives earlier this year.

Glimcher was the corresponding author on the paper, the seventh authored by a top DFCI researcher to be retracted this year.

In January, four DFCI executives – Glimcher, Executive Vice President and COO William C. Hahn ’87, Senior Vice President for Experimental Medicine Irene M. Ghobrial, and Harvard Medical School professor Kenneth C. Anderson – were accused of manipulating figures in a slew of papers scrutinized in a Jan. 2 blog post by data sleuth Sholto David.

Following David’s allegations, DFCI retracted six papers and issued corrections to 31 others in late January.

The first author on the retracted paper — Buck Institute researcher Claudio Hetz — was investigated in 2021 for allegedly altering images in more than 20 articles published between 2002 and 2021. A committee formed at the University of Chile found him not guilty of scientific fraud, but cited “an enormous carelessness and lack of rigor” in a ten-page report following the inquiry.

Hetz disagreed with the decision to retract, and four authors could not be reached for comment, according to the retraction. The statement did not mention Glimcher.

Investigation of this paper began more than two years ago, according to the retraction.

“Based on an internal analysis that began in February 2021, the authors have become aware of discrepancies in the controls,” the retraction stated.

“The authors are no longer confident that these figures support the conclusions. As a result, the authors are retracting the paper,” the retraction note added.

“As journals complete their review of the information Dana-Farber authors have submitted to them, the publishers will decide whether and when to publish corrections or retractions,” a DFCI spokesperson wrote in an emailed statement.

“We encourage them to do so promptly so that the scientific record is accurate. This process is ongoing,” she added.

Glimcher did not immediately respond to a request for comment.

—Staff writer Veronica H. Paulus can be reached at veronica.paulus@thecrimson.com. Follow her on X @VeronicaHPaulus.

—Staff writer Akshaya Ravi can be reached at akshaya.ravi@thecrimson.com. Follow her on X @akshayaravi22.

Want to keep up with breaking news? Subscribe to our email newsletter.

Tags
ResearchScienceBostonMedicineLongwoodFeatured ArticlesResearch MisconductFront Bottom Feature